WP
MREO

Woodline Partners’s Mereo BioPharma MREO Stock Holding History

Woodline Partners’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-947,986
Closed -$2.13M – 1012
2025
Q1 		$2.13M Buy
947,986
+329,202
+53% +$931K 0.01% 656
2024
Q4 		$2.17M Buy
+618,784
New +$2.43M 0.01% 642

Other funds holding MREO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Woodline Partners's MREO Position: Q2 2025 in Review

Woodline Partners sold out of Mereo BioPharma (MREO) in Q2 2025, closing a stake of 947,986 shares — an estimated $2.13M sold.

Woodline Partners first reported a position in MREO in Q4 2024 and held it in 2 quarters. The position peaked at $2.17M in Q4 2024. 86 funds tracked by Wall St. Rank hold MREO as of Q2 2025.

  • Woodline Partners reported no remaining Mereo BioPharma position as of Q2 2025 after selling out during the quarter.
  • Woodline Partners sold 947,986 Mereo BioPharma shares in Q2 2025, an estimated $2.13M.
  • Woodline Partners first reported a position in Mereo BioPharma in Q4 2024 and held it in 2 quarters.
  • Woodline Partners's Mereo BioPharma position peaked at $2.17M in Q4 2024.
  • 86 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2025.

Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.